ESSA Pharma Inc. (NASDAQ:EPIX) stock observed trading -26.68% off 52-week high price. On the other end, the stock has been noted 219.15% away from low price over the last 52-weeks. The stock disclosed a move of 7.91% away from 50 day moving average and 8.19% away from 200 day moving average. Moving closer, we can see that shares have been trading 8.67% off 20-day moving average. It has market cap of $93.43M.

On May 07, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2020. All references to $ in this release refer to United States dollars, unless otherwise indicated.

This past quarter has seen ESSA achieve a significant milestone as we filed the IND for EPI-7386 on time, and subsequently received allowance from the FDA to proceed with the Phase I clinical trial of EPI-7386, stated David Parkinson, MD, President and CEO of ESSA. Dr. Parkinson continued, We are currently working with clinical sites in the US and Canada so we can begin enrollment of patients as soon as possible, ensuring compliance with COVID-19 risk management guidance as provided by the FDA.

Recent Corporate Highlights

  • The Investigational New Drug (IND) application for EPI-7386 was filed and accepted by the Food and Drug Administration (FDA), and a clinical trial application (CTA) was subsequently filed with Health Canada. The clinical trial is expected to enroll approximately 18 patients at multiple medical institutions in a standard 3+3 trial design with an approximate 10 additional patients enrolled in the dose expansion cohort.
  • Entered into an Open Market Sale Agreement (the ATM Sales Agreement) with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in at-the-market transactions.
  • The Company will present posters with preclinical data on EPI-7386 at both the American Urological Association Annual Meeting to be held virtually on May 18, 2020 and the AACR Virtual Annual Meeting II held from June 22-24th. The poster presentations will include new gene expression data for EPI-7386, enzalutamide and the combination of the two in prostate cancer models.
  • The ESSA management team will participate in Jefferies Virtual Healthcare Conference from June 2-4, 2020.

The Canada based company ESSA Pharma Inc. moved with change of -0.88% to $4.5 with the total traded volume of 6970 shares in recent session versus to an average volume of 33.13K. The stock was observed in the 5 days activity at 3.33%. The one month performance of stock was 18.42%. EPIX’s shares are at -15.09% for the quarter and driving a 72.69% return over the course of the past year and is now at -18.18% since this point in 2018. The average volatility for the week and month was at 6.12% and 5.09% respectively. There are 20.76M shares outstanding and 7.16M shares are floated in market.